thrombolytics a field in development

Rivista Italiana di Neurobiologia

Volumn 4, Issue 1, 2007, Pages 7-14

  Petersen, Karl Uwe ^a  

^a PAION Deutschland GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFIMEPRASE; ALTEPLASE; ANCROD; DESMOTEPLASE; HEPARIN; LANOTEPLASE; MICROPLASMIN; PAMITEPLASE; PLACEBO; PROUROKINASE; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; UNCLASSIFIED DRUG; UROKINASE;

ALLERGIC REACTION; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; LUNG EMBOLISM; NEUROMODULATION; NONHUMAN; RECANALIZATION; REVIEW;

EID: 55549106465     PISSN: 00356336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Basanova AV, Baskova IP, Zavalova LL. Vascular-platelet and plasma hemostasis regulators from bloodsucking animals. Biochemistry (Moscow), 67:143-150 (2002)
2. Blann AD, Landray MJ, Lip GYH. ABC of antithrombotic therapy. An overview of antithrombotic therapy. BMJ 325: 762-765 (2002)
3. Beiwood J, Morton PA. Vampires: The real story. Bats 9: 11-16 (1991)
4. Benchenane K, Lopez-Atalaya JP, Fernandez-Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 27: 155-160 (2004)
5. Boehringer Ingelheim. Metalyse. Summary of product characteristics. (2004) http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid= 5532 (accessed October 31, 2006).
6. Boehringer Ingelheim. Metalyse. Scientific Discussion. (2005) http://www.emea.eu.int/humandocs/Humans/EPAR/metalyse/metalyse.htm (accessed November 16, 2006)
7. Bringmann P, Gruber D, Liese A, Toschi L, Krätzschmar J, Schleuning WD, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 27: 25596-25603 (1995)
8. Castel H, Roussel BD, Ali C, Maubert E, Ali C, Montaner J, Vivien D. Tissue plasminogen activator (tPA)-dependent cleavage of the NMDA receptor NR1 subunit occurs in vivo: Relevance to stroke. Proceedings 36th Annual Meeting of the Society for Neuroscience held in Atlanta, Georgia, USA, October 14-18 (2006)
9. Collen D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 93: 857-865 (1996)
10. Deitcher SR, Toombs CF. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase. Pathophysiol Haemost Thromb 34:215-220 (2005)
11. del Zoppo, GD, von Kummer, R, Hamann, G. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J. Neurol. Neurosurg. Psychiatry 65:1-9 (1998)
12. Epple G, Kettelgerdes G, Köttgen E, Geßner R, Schleuning W-D, Praus M. Stimulation of Plasminogen Activation by Recombinant Prion Protein is Specific for Tissue-type Plasminogen Activator. J Thromb Haemost 2: 962-968 (2004)
13. Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, Leveille F, Cacquevel M, Plawinski L, MacKenzie ET, Bu G, Buisson A, Vivien D. Is tissue-type plasminogen activator a neuromodulator? Mol Cell Neurosci 25: 594-601 (2004)
14. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W, DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset Stroke 37: 1227-1231 (2006)
15. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282: 2003-2011 (1999)
16. Goldhaber SZ. Thrombolysis in pulmonary embolism: A debatable indication. Thromb Haemost 86: 444-451 (2001)
17. GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 337:1118-1123 (1997)
18. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan, A, Kaste M, Lees KR, Soehngen M, Warach S for The DIAS Study Group. The desmoteplase in acute ischemic stroke trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36: 66-73 (2005)
19. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM, and the TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36: 607-612 (2005)
20. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM, ESTAT investigators. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 25 368:1871-1878 (2006)
21. Heymans S, Vanderschueren S, Verhaeghe R, Stockx L, Lacroix H, Nevelsteen A, Laroche Y, Collen D. Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion. Thromb Haemost 83: 666-671 (2000)
22. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 332: 349-360 (1988)
23. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M, and the PROACT II Investigators. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke The PROACT II trial. Neurology 57: 1603-1610 (2001)
24. Kruithoff EK, Schleuning W-D. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator. Thromb Haemost 92: 559-567 (2004)
25. Lee DH, Jo KD, Kim HG, Choi S-J, Jung SM, Ryu DS, Park MS. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol 13: 769-773 (2002)
26. Liberatore GT, Samson A, Bladin C, Schleuning W-D, Medcalf RL. Vampire bat salivary plasminogen activator (Desmoteplase), a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 34: 537-543 (2003)
27. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 113:38-48 (2004)
28. Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Lett 579:3303-3309 (2005)
29. López-Atalaya JP, Roussel BD, Levrat D, Nicole O, Benchenane K, Castel H, Leprince J, Hommet Y, To Van D, Sopkova-de Oliveira Santos J, Bureau R1 Rault S, Vaudry H, Petersen K-U, Ali C, Vivien D. Molecular requirements for modulation of NMDA receptor signaling by tissue-type plasminogen activator. Proceedings of the 18th International Congress on Fibrinolysis and Proteolysis (ICFP): Proteolysis in the Postgenomic Era held in San Diego, California, USA, August 27-31 (2006)
30. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 36: 2311-2320 (2005)
31. Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335:145-150 (1996)
32. Nagai N, Demarsin E, van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 1: 307-313 (2003)
33. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7: 59-64 (2001)
34. Nordt TK, Bode C. Thrombolysis: Newer thrombolytic agents and their role in clinical medicine. Heart 89:1358-1362 (2003)
35. Ouriel K. Safety and efficacy of the various thrombolytic agents. Rev Cardiovasc Med 3 (suppl 2): S17-S24 (2002)
36. Ouriel K, Castaneda F, McNamara T, Swischuk J, Tepe G, Smith JJ, Clark J, Duda S. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial. J Vasc Interv Radiol 15: 229-238 (2004)
37. Pfefferkorn T, Wiessner C, Allegrini PR, Kloss CUA, Hamann GF. MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia. Neurol Res 24: 822-824 (2002)
38. Pugsley MK, Lipka L, Petersen K-U, Soehngen M. A new hope for stroke? Evidence for the use of rDSPAá1 (desmoteplase) in acute ischemic stroke. Proc West Pharmacol Soc (in press)
39. Reddrop C, Moldrich RX, Beart PM, Farso M, Liberatore GT, Howells DW, Petersen K-U, Schleuning W-D, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 36: 1241-1246 (2005)
40. Ringleb PA, Schellinger PD, Schranz C, Hacke W. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful? Stroke 33: 1437-1441 (2002)
41. Schleuning W-D. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): A thrombolytic drug optimized by natural selection. Haemostasis 31: 118-122 (2001)
42. Sugg RM, Noser EA, Shaltoni HM, Gonzales NR, Campbell MS, Weir R, Cacayorin ED, Grotta JC. Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke. Am J Neuroradiol 27: 769-773 (2006)
43. Stewart RJ, Fredenburgh JC, Weitz JI. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer concovalently linked to fragment E. J Biol Chem 273: 18292-18299 (1998)
44. Sumii T, Lo EH, Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33: 831-836 (2002)
45. Suzuki Y, Nagai N, Collen D. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. J J Thromb Haemost, 2: 1617-1621 (2004)
46. Swenson S, Toombs CF, Pena L, Johansson J, Markland FS Jr. Alpha-fibrinogenases. Curr Drug Targets Cardiovasc Haematol Disord 4: 417-435 (2004)
47. Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, Van de Werf F. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 92:2044-2049 (1995)
48. Vivien D, López-Atalaya JP, Roussel BD, Ali C, Maubert E, Orset C, Berezowski V, Cecchelli R, Petersen K-U., Berezowski V, Cecchelli R, Orset C, Vivien D: Desmoteplase crosses the blood-brain barrier through an LDL receptor-related protein-dependent mechanism without exerting neurotoxic effects. Proceedings 36th Annual Meeting of the Society for Neuroscience held in Atlanta, Georgia, USA, October 14-18 (2006)
49. Yepes M, Lawrence DA. Tissue-type plasminogen ayctivator and neuroserpin: A well-balanced act in the nervous system? Cardiovasc Med 14:173-180 (2004)
50. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112: 1533-1540 (2003).